Buradasınız

Uludağ Üniversitesi Yenidoğan İşitme Taraması Sonuçları

Newborn Hearing Screening Outcomes at Uludağ University

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
In order to initiate newborn hearing screening program at Uludağ University, transient-evoked otoacoustic emisssion (TEOAE) test was performed on 402 newborns between February 2005 – February 2006. Additionally, the risk factors for newborn hearing losses were inquired. 219 newborns passed TEOAE test at the first examination; in 183 newborns the test results were suspicious. Only 24 of 183 newborns, who were called for the second test, attended and all passed. The risk factors for probable hearing loss (drug use in mother, aminoglicozide use in newborn etc.) were found in 125 of 219 newborns who passed in the first test and 115 of 183 newborns who failed in the first test. Although, hearing loss were diagnosed in none of the children from both groups, routine use of newborn hearing screening was suggested to diagnose the newborn hearing losses in the expected ratio of the population, however, the low rate of attendance to control decreased the efficacy of the screening.
Abstract (Original Language): 
Hastanemizde yenidoğanlarda işitme taraması uygulamasının başlatılması amacıyla Şubat 2005 – Şubat 2006 tarihleri arasında Uludağ Üniversitesi Tıp Fakültesi’nde doğan 402 bebeğe Transient Uyarılmış Oto Akustik Emisyon ( TEOAE) testi uygulandı. Ek olarak yenidoğan işitme kaybı açısından belirlenen risk faktörleri sorgulandı. 219 yenidoğan bebek ilk testi geçti, 183 yenidoğanda ilk testte şüpheli sonuç elde edildi. Kontrole çağrılan bebeklerden sadece 24’ü geldi ve tamamı ikinci testi geçti. İlk aşamada testi geçemeyen 183 bebeğin 115’inde ve ilk aşama testi geçen 219 bebeğin ise 125’inde yenidoğan işitme kaybına neden olabilecek risk faktörleri saptandı ( annede ilaç kullanımı, bebekte aminoglikozid kullanımı vb.). Hiçbir grupta işitme kayıplı bebek saptanmamasına rağmen yenidoğan işitme taramasının rutin olarak uygulanmasının toplumda öngörülen sıklıkta yenidoğan işitme kayıplarını ortaya çıkaracağı ancak kontrole gelen hasta sayısının düşük olması taramanın verimliliğini düşürdüğü sonucuna varıldı.

REFERENCES

References: 

1. Thompson DC, McPhillips H, Davis RL, Lieu TL, Homer CJ,
Helfand M. Universal newborn hearing screening: Summary of
evidence. JAMA 2001; 286: 2000-2010.
2. Oudesluys-Murphy AM, Van Straaten HL, Bholasingh R, Van
Zanten GA. Neonatal hearing screening. Eur J Pediatr 1996;
155: 429-35.
3. Kemp DT, Ryan S, Bray P. A guide to the effective use of
otoacoustic emissions. Ear Hear 1990; 11: 93-105.
4. Turkewitz G, Kenny PA. The role of developmental limitations
of sensory input on sensory/perceptual organization. J Dev
Behav Pediatr. 1985 Oct;6(5):302-6. Review.
5. Committee on İnfant Hearing 1994 Position Statement.
American Academy of Pediatrics Joint Committee on İnfant
Hearing. Pediatrics 1995; 95:152-6.
6. Mazurek B, Winter E, Fuchs J, Haupt H, Gross J. Susceptibility
of the hair cells of the newborn rat cochlea to hypoxia and
ischemia. Hear Res. 2003 Aug;182(1-2):2-8.
7. Newton V. Adverse perinatal conditions and the inner ear.
Semin Neonatol. 2001 Dec;6(6):543 - 51. Review.
8. Merchant SN, Gopen Q. A human temporal bone study of acute
bacterial meningogenic labyrinthitis. Am J Otol. 1996
May;17(3):375 - 85.
9. Martin WH, Schwegler JW, Gleeson AL, et al. New techniques
of hearing assessment. Otolaryngol Clin North Am 1994;
27(3):487 - 510.
10. Morgan DE, Canalis RF. Auditory screening of infants.
Otolaryngol Clin North Am 1991: 24(2):277 - 84.
11. Lafreniere D, Smurzynski J, Jung M, et al. Otoacoustic
emissions in full term newborns at risk for hearing loss.
Laryngoscope 1993; 103(12):1334 - 41.
12. Kemp DT, Ryan S. The use of transient evoked otoacoustic
emissions in neonatal hearing screening programs. Semin Hear
1993; 14: 30 - 45.
13. American Academy of Pediatrics. Task Force on Newborn and
Infant Hearing. Newborn and infant hearing loss: detection and
intervention. Pediatrics 1999; 103: 527- 30.

Thank you for copying data from http://www.arastirmax.com